All‐cause mortality · people with cancer who have febrile neutropenia
Pre‐emptive antifungal therapy showed no clear difference in all‐cause mortality compared with empirical antifungal therapy (low certainty).
1 finding from 1 review
Mortality ascribed to fungal infection · people with cancer who have febrile neutropenia
Pre‐emptive antifungal therapy showed no clear difference in mortality ascribed to fungal infection compared with empirical antifungal therapy (low certainty).
1 finding from 1 review
Proportion of antifungal agent use (other than prophylactic use) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes proportion of antifungal agent use (other than prophylactic use) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Duration of antifungal use (days) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes duration of antifungal use (days) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Invasive fungal infection detection · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes invasive fungal infection detection compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Adverse effects · people with cancer who have febrile neutropenia
1 finding from 1 review
Heart failure · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure Available case analysis compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Secondary malignant neoplasms · adults with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heart failure · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in clinical heart failure Available‐case analysis compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Cardiomyopathy/heart failure primary cause of death Available‐case analysis · children with cancer receiving anthracyclines
1 finding from 1 review
Clinical heart failure and subclinical myocardial dysfunction combined Defined as (1) evidence of clinical congestive heart failure, (2) a reduction in LVEF as measured by MUGA to < 45% or (3) a decrease in LVEF as measured by MUGA of > 20 percent... · children with cancer receiving anthracyclines
Dexrazoxane may leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Clinical heart failure and subclinical myocardial dysfunction combined Defined as clinical heart failure (no definition provided) or subclinical myocardial dysfunction defined as decreased LVFS; however, it was stated that toxicity was graded acco... · children with cancer receiving anthracyclines
1 finding from 1 review
Has died · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall mortality (Reported as number of participants who died) compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Progression‐free survival · children with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response rate Defined as number of complete remissions (no definition of complete remission provided). Best‐case analysis · children with cancer receiving anthracyclines
It is very uncertain whether dexrazoxane changes tumour response rate Defined as number of complete remissions (no… compared with no cardioprotective intervention (very low certainty).
1 finding from 1 review
Tumour response rate Defined as number of complete responses (i.e. disappearance of active Hodgkin lymphoma (gallium negative, ≥ 70% decrease in the sum of the products of the perpendicular diameters of measurable lesions, and negative bone marrow... · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete responses (i.e.… compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Quality of life · children with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical heart failure and subclinical myocardial dysfunction combined Comparable definitions; see Characteristics of included studies for exact definitions. Available‐case analysis · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention or placebo (moderate certainty).
2 findings from 1 review
Secondary malignant neoplasms · children with cancer receiving anthracyclines
Dexrazoxane may leads to higher secondary malignant neoplasms Available‐case analysis compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Overall survival (Illustrative comparative risks reported as number of alive participants) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall survival (Illustrative comparative risks reported as number… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review